Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September
September 03 2020 - 8:00AM
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage,
biopharmaceutical company dedicated to developing and
commercializing first-in-class, oral enzyme therapeutics to treat
patients with rare and severe metabolic and kidney disorders, today
announced that company management will participate in fireside
chats at two investor conferences in September:
Baird 2020 Global Healthcare Conference
Date: Thursday, September 10
Time: 9:40 a.m. ET
H.C. Wainwright & Co. 22nd Annual Global Investor
Conference Date: Tuesday, September 15
Time: 12:30 p.m. ET
Live audio webcasts of the presentations will be available under
“Events and Presentations” in the Investors section of the
Company’s website at www.allenapharma.com. Replays of the
webcasts will be available on the Allena website for 30 days
following each presentation.
About Allena Pharmaceuticals Allena
Pharmaceuticals, Inc. is a late-stage biopharmaceutical
company dedicated to developing and commercializing first-in-class,
oral enzyme therapeutics to treat patients with rare and severe
metabolic and kidney disorders. Allena’s lead product candidate,
reloxaliase, is a first in class, oral enzyme therapeutic for the
treatment of hyperoxaluria, a metabolic disorder characterized by
markedly elevated urinary oxalate levels and commonly associated
with kidney stones, chronic kidney disease and other serious kidney
disorders.
Investor Contact Hannah Deresiewicz Stern
Investor Relations, Inc.
212-362-1200hannah.deresiewicz@sternir.com
Media Contact Adam Daley Berry & Company
Public Relations 212-253-8881adaley@berrypr.com
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Sep 2023 to Sep 2024